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Abstract  
Sodium valproate a broad spectrum antiepileptic elevates the brain GABA levels. Studies have suggested regulatory role of 
GABA on dopaminergic neurons, which is evident by behavioral studies in animals that reveal functional interaction between 
GABAergic and DAergic systems. Hyperfunctioning of DAergic system in rats is responsible for occurrence of stereotyped 
behavior (SB) in them. Drugs like apomorphine (Apo) and amphetamine induce SB by acting directly or indirectly. GABA, by 
acting at different sites has shown to influence the dopaminergically mediated behaviors. Hence the study was taken up to 
investigate the effect of sodium valproate pretreatment on apomorphine and dexamphetamine induced SB in rats. 
Pretreatment with 100 to 400mg/kg sodium valproate did not antagonize the apomorphine induced SB, however pretreatment 
with 100 to 400mg/kg sodium valproate significantly antagonized SB induced by 10 & 15mg/kg dexamphetamine. 
 




     Sodium valproate elevates the brain GABA levels and thereby 
enhances the GABAergic neurotransmission, [1] by stimulating the 
activity of the GABA synthetic enzymes and by inhibiting the GABA 
degradative enzymes. 
     Histological, electrophysiological and biochemical studies 
suggest a regulatory role of GABA on the dopaminergic (DAergic) 
neurons [2].Behavioral studies in animals have provided an additional 
evidence for a functional interaction between GABAergic and 
DAergic system. Drugs known to influence the central GABAergic 
systems have been reported to modulate the intensity of behaviors 
dependent on the functioning of the nigrostriatial and mesolimbic 
DAergic systems [3, 4]. 
     Hyperfunctioning of nigrostriatal DAergic system in rats is 
responsible for occurrence of the stereotyped behavior (SB) of oral 
movement variety characterized by repetitive sniffing, gnawing, biting 
or licking behavior. Drugs like apomorphine and amphetamine 
induce SB either by acting directly or indirectly on the post synaptic 
striatal D2DA receptors. Neuroleptics like haloperidol block the 
postsynaptic D2DA receptors, and antagonize the SB induced by DA 
agonists [5]. 
     GABA and GABA mimetic agents injected in pars compacta 
region of substantia nigra, exert a direct inhibitory influence on the 
functioning of the nigrostriatal DAergic neurons. However, when 
injected in pars reticulate they exert excitatory effect that is 
postulated to be due to inhibition of GABA and GABA mimetic agents 
or by inhibition of DA release. 
     Thus GABA by acting at different sites in nigrostriatal and 
mesolimbic DAergic system can differently modulate the functioning 
of these systems.  
     Since it has been reported that the central GABAergic 
systems modulate the activity of nigrostriatal and mesolimbic 
DAergic systems and have shown to influence DAergically mediated 
behaviors the study was taken up to investigate the effect of sodium 
valproate pretreatment on the apomorphine and dexamphetamine 
induced SB in rats. 
 
MATERIALS AND METHODS 
 
     Albino rats of either sex, weighing between 100-180g, were 
used. They were allowed food and water ad libitum up to time of 
experimentation. Each animal was used only once. All observations 
were made between 10-17 hours at 27-300C in a noiseless, diffusely 
illuminated room. Each group consisted of 10 animals. 
     The drugs used were Sodium Valproate (Reckitt and Colman), 
Apomorphine hydrochloride (Sigma), Dexamphetamine sulphate 
(Koch Light), Haloperidol (Seranace injection, Searle). Haloperidol 
injection was diluted in distilled water. Apomorphine was dissolved in 
the distilled water containing 0.2mg/ml ascorbic acid while the 
remaining drugs were dissolved in distilled water only. 
     All drug solutions were prepared immediately before use and 
were injected intraperitoneally. The volume of injection was 5ml/kg 
body weight for valproate while for remaining drugs it was 2ml/kg 
body weight. 
     For observation of SB, the rats were placed in individual 
cages made of wire netting, measuring 30x20x20 cm, 30 min before 
drug treatment to allow adaptation to the new environment. 
     The intensity of SB was assessed over a 30 sec observation 
period at 10 min interval throughout its duration using the system of 
Costall and Naylor [6], where, periodic sniffing= score 1, continuous 
sniffing =2, periodic biting ,gnawing or licking=3, and continuous 
biting ,gnawing or licking=4. The maximum intensity of SB scored by 
each rat in the group was taken to compute the mean value of the 
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     Sodium valproate and haloperidol were injected 1hr before 
apomorphine or dexamphetamine. The control groups received 
requisite volume of normal saline (NS) ip, 1hr before receiving 
apomorphine or dexamphetamine. Sodium valproate was tested in 
the dose range of 50 to 400mg/kg while haloperidol was tested in the 
dose of 0.5mg/kg. 
     The study was undertaken at Krishna institute of Medical 
Sciences, Karad. Maharashtra. All the procedures were performed in 
accordance with CPCSEA guidelines & the study was carried on 





     The results were statistically analyzed by the students 
unpaired t-test with the differences considered significant at p<0.05. 
 
OBSERVATIONS AND RESULTS 
 
     Sodium valproate (50 to 400mg/kg) did not induce SB in rats. 
Apomorphine (0.5 and 1mg/kg) induced dose dependent SB in rats 
(Table -1). Pretreatment with sodium valproate (50 to 400mg/kg) did 
not significantly influence apomorphine induced SB. However, 
pretreatment with 0.5 mg/kg haloperidol abolished SB induced by 0.5 
and 1mg/kg apomorphine (Table-1)
 
Table 1.Effect of Sodium Valproate (VAL) and Haloperidol (HAL) pretreatment on Apomorphine (Apo) induced SB in rats. 
 
Study  Treatment dose mg/kg Intensity score Mean ±SEM 
I A 1 NS + Apo 0.5 1.2 ± 0.13 
 2 VAL 50 + Apo 0.5 1.3 ± 0.15 
 3 VAL 100 + Apo 0.5 1.0 ± 0.00 
 4 VAL 150 + Apo 0.5 1.1 ± 0.10 
 5 VAL 200 + Apo 0.5 1.2 ± 0.13 
 6 VAL 300 + Apo 0.5 1.0 ± 0.00 
 7 VAL 400 + Apo 0.5 1.1 ± 0.10 
I B 1 NS + Apo 0.5 1.2 ± 0.13 
 2 HAL 0.5 + Apo 0.5 0.0 
IIA 1 NS + Apo 1 2.1 ± 0.10 
 2 VAL 50 + Apo1 2.2 ± 0.13 
 3 VAL 100 + Apo1 2.1 ± 0.10 
 4 VAL 150 + Apo 1 2.0 ± 0.00 
 5 VAL 200 + Apo 1 2.2 ± 0.13 
 6 VAL 300 + Apo 1 2.3 ± 0.15 
 7 VAL 400 + Apo 1 2.1 ± 0.10 
IIB 1 NS + Apo 1 2.2 ± 0.13 
 2 HAL 0.5 + Apo 1 0.0 
                               NS= Normal Saline (5ml/kg ip for valproate control groups and 2ml/kg ip for haloperidol control groups). 
 
     Similarly, dexamphetamine (10 and 15mg/kg) induced dose dependent SB in 
rats (Table-2). Pretreatment with 50mg/kg sodium valproate did not significantly 
influence SB induced by 10 and 15mg/kg dexamphetamine. However pretreatment 
with 100 to 400mg/kg sodium valproate significantly antagonized the SB induced by 
10 and 15mg/kg dexamphetamine. Pretreatment with 0.5mg/kg haloperidol abolished 
the SB induced by 10 and 15mg/kg dexamphetamine. (Table-2) 
 
Table 2. Effect of Sodium Valproate (VAL) and Haloperidol (HAL) pretreatment on Dexamphetamine (DAM) induced SB in rats. 
 
Study  Treatment dose mg/kg Intensity score Mean ± SEM 
IA 1 NS + DAM 10 3.0 ± 0.00 
 2 VAL 50 + DAM 10 2.8 ± 0.13 
 3 VAL 100 + DAM 10 2.4 ± 0.16* 
 4 VAL 150 + DAM 10 2.0 ± 0.12** 
 5 VAL 200 + DAM 10 1.2 ± 0.13*** 
 6 VAL 300 + DAM 10 0.5 ± 0.16*** 
IB  1 NS + DAM 10 3.0 ± 0.10 
 2 HAL 0.5 + DAM 10 0.0 
IIA 1 NS + DAM 15 3.9 ± 0.10 
 2 VAL 50 + DAM 15 3.7 ± 0.15 
 3 VAL 100 + DAM 15 3.3 ± 0.15* 
 4 VAL 150 + DAM15 2.9 ± 0.10** 
 5 VAL 200 + DAM 15 2.1 ± 0.10*** 
 6 VAL 300 + DAM 15 1.4 ± 0.16*** 
 7 VAL 400 + DAM 15 0.7 ± 0.15*** 
IIB 1 NS + DAM 15 4.0 ± 0.00 
 2 HAL 0.5 + DAM 15 0.0 
                                  *p<0.05, **p<0.01, ***p <0.001. 
                                NS= Normal saline (5ml/kg ip for valproate control groups and 2ml/kg ip for Haloperidol control groups) 
 
SUMMARY AND CONCLUSIONS 
 
     Behavioral studies in animals have demonstrated that drugs 
which influence the activity of central GABAergic system modulate 
the intensity of behaviors on the functional status of nigrostriatal and 
mesolimbic DAergic systems. Histological studies have 
demonstrated an anatomical connection between the central 
serotonergic and dopamiergic pathway [7, 8].Behavioral studies have 
shown that 5HT inhibits the synthesis and release of DA from rat 
brain by stimulating 5HT receptors. Since the 5HT induced inhibition 
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of DA release is blocked by 5HT2 receptor antagonists [9].With 
present study it was evident that pretreatment with 100,150,200,300 
and 400mg/kg of sodium valproate, did not induce catalepsy nor 
antagonized the apomorphine induced SB in rats, it indicates that 
valproate at these doses does not block the post synaptic striatal 
D2DA receptors. However, pretreatment with 0.5mg/kg haloperidol 
abolished the SB induced by 0.5 & 1mg/kg apomorphine. (Table-1) 
     The antagonism of dexamphetamine SB by valproate (Table-
2) is explained as follows. Dexamphetamine induce SB of the oral 
movement variety, by releasing DA from the nigrostriatal DAergic 
neurons with resultant stimulation of post synaptic striatal D2DA 
receptors by the released DA [10]. The intensity of dexamphetamine 
SB depends upon the availability of the intraneuronal stores of DA 
for release by dexamphetamine. 
     Benzodiazepines, which enhance GABAergic transmission at 
GABAA receptor site, have been reported to potentiate the DA 
dependent SB induced by methamphetamine in rats [11]. 
     Pretreatment with 5HT precursors (5- Hydroxytrytophan, L-
tryptophan) antagonized, while pretreatment with methysergide a 
5HT antagonist and p-chlorophenylalanine (PCPA), a 5HT depletor, 
potentiated amphetamine stereotype behavior [12].  
     GABA-T inhibitor amino-oxyaceticacid (AOAA) elevates the 
brain GABA levels and thereby inhibit DA turnover (decreases the 
synthesis and release of DA). Similarly intraventricular or intranigral 
injection of GABA-T inhibitor ethanolamine-o-sulphate (EOS) also 
results in a decreased levels of DA metabolite 3-methoxy tyramine 
(3-MT), indicating that GABA decreases the release of DA from the 
nigrostriatal DAergic neurons [13]. Like GABA, 5-HT has also been 
reported to inhibit synthesis and release of DA from the nigrostriatal 
DAergic neurons [14].  
     Based on the findings we postulate that, valproate at 100 and 
150mg/kg doses, by elevating the brain GABA levels and at 200, 300 
and 400mg/kg doses, additionally by releasing 5-HT exerts inhibitory 
effect on nigrostriatal DAergic neurons and decreases the synthesis 
of DA in the nigrostriatal DAergic neurons. As a consequence the 
intraneuronal stores of DA decrease and less amount of DA is 
therefore available for release by dexamphetamine with resultant 
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